Show simple item record

dc.creatorPopović, M.
dc.creatorPopović, N.
dc.creatorJovanova-Nešić, Katica
dc.creatorBokonjić, D.
dc.creatorDobrić, Silva
dc.creatorRosić, N.
dc.date.accessioned2021-02-18T10:20:05Z
dc.date.available2021-02-18T10:20:05Z
dc.date.issued1997
dc.identifier.issn0020-7454
dc.identifier.urihttp://intor.torlakinstitut.com/handle/123456789/77
dc.description.abstractThe present study was done to investigate and compare the effect of acetylcholinesterase inhibitor, physostigmine (0.030, 0.045, 0.060 and 0.075 mg/kg sc) and Ca-antagonist, verapamil (1.0, 2.5, 5.0 and 10.0 mg/kg sc) on open field behavior in male Wistar rats with bilateral electrolytic lesions of nucleus basalis magnocellularis (NBM). NBM-lesions produced a significant increase and decrease of ambulation and number of inner squares entered, and defecation, respectively, with no influence on grooming in rats exposed to novel environment. Physostigmine and verapamil in all tested doses, given 30 min before the test did not affect the open field behavior in control animals. In contrast to that, physostigmine (0.045, 0.060 and 0.075 mg/kg) and verapamil (2.5 and 5.0 mg/kg) significantly reduced ambulation and number of inner squares entered in NBM-lesioned rats. Also, physostigmine in a dose of 0.060 mg/kg significantly decreased defecation and in doses of 0.060 and 0.075 mg/kg the grooming, as well. On the other hand, verapamil only in a dose of 2.5 mg/kg significantly increased defecation. It could be concluded that lesions of NBM in rats induced disturbances in the open field behavior, which might be successfully ameliorate by physostigmine and verapamil treatment.en
dc.publisherTaylor & Francis Ltd, Abingdon
dc.rightsrestrictedAccess
dc.sourceInternational Journal of Neuroscience
dc.subjectAlzheimer's diseaseen
dc.subjectnucleus basalis magnocellularisen
dc.subjectopen fielden
dc.subjectphysostigmineen
dc.subjectverapamilen
dc.subjectratsen
dc.titleOpen field behavior in nucleus basalis magnocellularis-lesioned rats treated with physostigmine and verapamilen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage188
dc.citation.issue3-4
dc.citation.other91(3-4): 181-188
dc.citation.spage181
dc.citation.volume91
dc.identifier.doi10.3109/00207459708986375
dc.identifier.pmid9394225
dc.identifier.rcubconv_504
dc.identifier.scopus2-s2.0-0031259859
dc.identifier.wosA1997YE86000004
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record